Scandinavian Medical Solutions (SMSMED) Investor Update summary
Event summary combining transcript, slides, and related documents.
Investor Update summary
26 Dec, 2025Guidance adjustment and financial outlook
Revenue guidance for the fiscal year was revised from DKK 240–270 million to DKK 200–240 million, and EBITDA from DKK 24–29 million to DKK 11–15 million.
The adjustment is driven by geopolitical uncertainty, potential tariffs on exports to the US, and a weaker US dollar impacting margins and customer buying power.
Shorter order book visibility and customer hesitancy, especially in the US, have reduced the ability to forecast long-term sales.
Margin pressure is attributed to the inability to hedge currency risk and the need to maintain market momentum despite lower profitability.
Market and operational dynamics
US customers are delaying orders due to tariff uncertainty and currency fluctuations, affecting both demand and order book duration.
The rental business shows positive traction with strong interest, particularly in the US, but larger projects take longer to materialize.
The company’s US presence provides strategic flexibility to source and sell equipment domestically, mitigating tariff risks.
Private healthcare in the US is expected to drive demand for used equipment, benefiting the business model.
Cost management and strategic response
Cost-saving initiatives include consolidating positions, optimizing warehousing, and maintaining a prudent approach to hiring.
Growth investments will continue, but with increased focus on cost control and cash flow management.
The company is financially robust and prepared to execute contingency plans depending on future tariff outcomes.
Latest events from Scandinavian Medical Solutions
- Revenue and EBITDA met guidance, with full rental fleet utilization and U.S. expansion fueling growth.SMSMED
H2 23/2412 Jan 2026 - Revenue up 8%, but EBITDA and net profit declined sharply amid higher costs and market volatility.SMSMED
H2 24/2520 Nov 2025 - Revenue up 20% but margins pressured by costs, volatility, and leadership transition.SMSMED
H1 24/255 Jun 2025